BACKGROUND: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the first disease-specific instrument for assessing patient-reported symptoms, functioning and quality of life (QoL) in pulmonary arterial hypertension (PAH). OBJECTIVES: To create and validate French-Canadian (FC) and English-Canadian (EC) language versions of the CAMPHOR. METHODS: A translation panel (for the FC version) and lay panels (for both versions) were convened to adapt the questionnaires (dual-panel methodology). Subsequently, these new questionnaires were field-tested in 15 FC PAH and 15 EC PAH patients. Finally, in a postal validation study, the new language versions of the CAMPHOR underwent psychometric evaluation in 41 FC and 52 EC PAH patients to test for reliability and validity. RESULTS: The FC and EC field-test interview participants found the questionnaires relevant, comprehensible and easy to complete. Psychometric analyses showed that the FC and EC adaptations were successful. High test-retest coefficients for the scales after controlling for change in respondent's QoL (FC: 0.92 to 0.96; EC: 0.85 to 0.99) indicated a high degree of reliability. The FC and EC CAMPHOR scales had good internal consistency (Cronbach's alpha coefficients 0.90 to 0.92 and 0.88 to 0.92, respectively). Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of the FC and EC scales. The FC and EC adaptations also showed known groups validity. CONCLUSIONS: The FC and EC adaptations of the CAMPHOR have been shown to be reliable and valid for measures of health-related QoL and QoL in PAH, and thus can be recommended for use in clinical studies and routine practice in PAH.
BACKGROUND: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the first disease-specific instrument for assessing patient-reported symptoms, functioning and quality of life (QoL) in pulmonary arterial hypertension (PAH). OBJECTIVES: To create and validate French-Canadian (FC) and English-Canadian (EC) language versions of the CAMPHOR. METHODS: A translation panel (for the FC version) and lay panels (for both versions) were convened to adapt the questionnaires (dual-panel methodology). Subsequently, these new questionnaires were field-tested in 15 FC PAH and 15 EC PAH patients. Finally, in a postal validation study, the new language versions of the CAMPHOR underwent psychometric evaluation in 41 FC and 52 EC PAH patients to test for reliability and validity. RESULTS: The FC and EC field-test interview participants found the questionnaires relevant, comprehensible and easy to complete. Psychometric analyses showed that the FC and EC adaptations were successful. High test-retest coefficients for the scales after controlling for change in respondent's QoL (FC: 0.92 to 0.96; EC: 0.85 to 0.99) indicated a high degree of reliability. The FC and EC CAMPHOR scales had good internal consistency (Cronbach's alpha coefficients 0.90 to 0.92 and 0.88 to 0.92, respectively). Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of the FC and EC scales. The FC and EC adaptations also showed known groups validity. CONCLUSIONS: The FC and EC adaptations of the CAMPHOR have been shown to be reliable and valid for measures of health-related QoL and QoL in PAH, and thus can be recommended for use in clinical studies and routine practice in PAH.
Authors: Nazzareno Galiè; Adam Torbicki; Robyn Barst; Philippe Dartevelle; Sheila Haworth; Tim Higenbottam; Horst Olschewski; Andrew Peacock; Giuseppe Pietra; Lewis J Rubin; Gerald Simonneau; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin Cowie; Verconcia Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; Keith McGregor; João Morais; Ali Oto; Otto A Smiseth; Joan Albert Barbera; Simon Gibbs; Marius Hoeper; Marc Humbert; Robert Naeije; Joanna Pepke-Zaba Journal: Eur Heart J Date: 2004-12 Impact factor: 29.983
Authors: S P McKenna; L C Doward; T Kohlmann; C Mercier; M Niero; M Paes; D Patrick; N Ramirez; H Thorsen; D Whalley Journal: J Affect Disord Date: 2001-03 Impact factor: 4.839
Authors: David B Badesch; Steve H Abman; Gregory S Ahearn; Robyn J Barst; Douglas C McCrory; Gerald Simonneau; Vallerie V McLaughlin Journal: Chest Date: 2004-07 Impact factor: 9.410
Authors: D Whalley; S P McKenna; A L Dewar; R A Erdman; T Kohlmann; M Niero; S A Cook; B Crickx; M J Herdman; F Frech; D Van Assche Journal: Br J Dermatol Date: 2004-02 Impact factor: 9.302
Authors: G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis Journal: Ann Intern Med Date: 1991-09-01 Impact factor: 25.391
Authors: Katarzyna Małaczynska-Rajpold; Anna Smukowska-Gorynia; Alice Heaney; Stephen P McKenna; Magdalena Janus; Aleksander Araszkiewicz; Stanislaw Jankiewicz; Sylwia Slawek-Szmyt; Iga Tomaszewska; Tatiana Mularek-Kubzdela Journal: Cardiol J Date: 2018-10-19 Impact factor: 2.737
Authors: Katharina Cima; James Twiss; Rudolf Speich; Stephen P McKenna; Ekkehard Grünig; Christian M Kähler; Nicola Ehlken; Ursula Treder; Sigrid R Crawford; Lars C Huber; Silvia Ulrich Journal: Health Qual Life Outcomes Date: 2012-09-13 Impact factor: 3.186
Authors: Janelle Yorke; Paul Corris; Sean Gaine; J Simon R Gibbs; David G Kiely; Carl Harries; Val Pollock; Iain Armstrong Journal: Eur Respir J Date: 2013-11-14 Impact factor: 16.671
Authors: Caio J C S Fernandes; Barbara C S Martins; Carlos V P Jardim; Rozana M Ciconelli; Luciana K Morinaga; Ana Paula Breda; Susana Hoette; Rogério Souza Journal: Health Qual Life Outcomes Date: 2014-08-30 Impact factor: 3.186
Authors: Abílio Reis; James Twiss; Margarida Vicente; Fabienne Gonçalves; Luísa Carvalho; José Meireles; Alzira Melo; Stephen P McKenna; Luís Almeida Journal: Health Qual Life Outcomes Date: 2016-07-26 Impact factor: 3.186
Authors: M Wapenaar; J Twiss; M Wagenaar; P Seijkens; L van den Toorn; J Stepanous; A Heaney; A van den Bosch; K A Boomars Journal: Neth Heart J Date: 2016-06 Impact factor: 2.380